109 related articles for article (PubMed ID: 27892948)
1. Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL).
Shah N; Rauenzahn S; Veltri L; Wen S; Craig M; Hamadani M; Kanate AS; Cumpston A
Bone Marrow Transplant; 2017 Feb; 52(2):321-322. PubMed ID: 27892948
[No Abstract] [Full Text] [Related]
2. High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.
Kondo E; Ikeda T; Izutsu K; Chihara D; Shimizu-Koresawa R; Fujii N; Sakai T; Kondo T; Kubo K; Kato Y; Akasaka T; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J; Suzuki R;
Biol Blood Marrow Transplant; 2019 May; 25(5):899-905. PubMed ID: 30664936
[TBL] [Abstract][Full Text] [Related]
3. Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma.
Fenske TS; Kahl BS; Eickhoff J; Mitchell TL; Smith EP; Atkinson E; McCoy AG; Eckstein L; Flynn B; McMannes J; Howard S; Longo WL
Leuk Lymphoma; 2005 Oct; 46(10):1441-8. PubMed ID: 16194889
[TBL] [Abstract][Full Text] [Related]
4. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
5. A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa.
McCoy AG; Smith EP; Atkinson ME; Baranski B; Kahl BS; Juckett M; Mitchell T; Gangnon R; Longo WL
Bone Marrow Transplant; 2004 Jan; 33(1):19-24. PubMed ID: 14704653
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma.
Lemieux C; Ahmad I; Bambace NM; Bernard L; Cohen S; Delisle JS; Fleury I; Kiss T; Mollica L; Roy DC; Sauvageau G; Roy J; Lachance S
Biol Blood Marrow Transplant; 2020 Jan; 26(1):157-161. PubMed ID: 31521818
[TBL] [Abstract][Full Text] [Related]
7. Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma.
Lee SC; Kim SJ; Lee DH; Kim WS; Suh C; Won JH
Bone Marrow Transplant; 2010 Apr; 45(4):801-2. PubMed ID: 19767780
[No Abstract] [Full Text] [Related]
8. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
[TBL] [Abstract][Full Text] [Related]
9. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
Demirer T; Ayli M; Fen T; Ozcan M; Arat M; Buyukberber S; Arslan O; Gurman G; Akan H; Ilhan O
Bone Marrow Transplant; 2004 Nov; 34(9):781-6. PubMed ID: 15354206
[TBL] [Abstract][Full Text] [Related]
10. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.
Qualls D; Sullivan A; Li S; Brunner AM; Collier K; Hochberg E; Armand P; Batchelor TT; Chen YB; DeFilipp Z
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):884-888. PubMed ID: 28870642
[TBL] [Abstract][Full Text] [Related]
11. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Chen YB; Lane AA; Logan B; Zhu X; Akpek G; Aljurf M; Artz A; Bredeson CN; Cooke KR; Ho VT; Lazarus HM; Olsson R; Saber W; McCarthy P; Pasquini MC
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1046-1053. PubMed ID: 25687795
[TBL] [Abstract][Full Text] [Related]
12. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.
Giulino-Roth L; Ricafort R; Kernan NA; Small TN; Trippett TM; Steinherz PG; Prockop SE; Scaradavou A; Chiu M; O'Reilly RJ; Boulad F
Pediatr Blood Cancer; 2013 Dec; 60(12):2018-24. PubMed ID: 24038967
[TBL] [Abstract][Full Text] [Related]
13. Inappropriate antidiuretic hormone secretion after high-dose thiotepa.
Sica S; Cicconi S; Sorà F; Chiusolo P; Piccirillo N; Laurenti L; La Barbera EO; Giordano G; Leone G
Bone Marrow Transplant; 1999 Sep; 24(5):571-2. PubMed ID: 10482945
[TBL] [Abstract][Full Text] [Related]
14. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest.
Sharp JG; Kessinger A; Mann S; Crouse DA; Armitage JO; Bierman P; Weisenburger DD
J Clin Oncol; 1996 Jan; 14(1):214-9. PubMed ID: 8558200
[TBL] [Abstract][Full Text] [Related]
15. Transplantation for non-Hodgkin lymphoma.
Nademanee A
Expert Rev Hematol; 2009 Aug; 2(4):425-42. PubMed ID: 21082947
[TBL] [Abstract][Full Text] [Related]
16. A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.
Smeland KB; Kiserud CE; Lauritzsen GF; Blystad AK; Fagerli UM; Falk RS; Fluge Ø; Fosså A; Kolstad A; Loge JH; Maisenhölder M; Østenstad B; Kvaløy S; Holte H
Br J Haematol; 2016 May; 173(3):432-43. PubMed ID: 26914167
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.
Bhatia R; Van Heijzen K; Palmer A; Komiya A; Slovak ML; Chang KL; Fung H; Krishnan A; Molina A; Nademanee A; O'Donnell M; Popplewell L; Rodriguez R; Forman SJ; Bhatia S
J Clin Oncol; 2005 Sep; 23(27):6699-711. PubMed ID: 16170178
[TBL] [Abstract][Full Text] [Related]
18. High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.
Schorb E; Fox CP; Fritsch K; Isbell L; Neubauer A; Tzalavras A; Witherall R; Choquet S; Kuittinen O; De-Silva D; Cwynarski K; Houillier C; Hoang-Xuan K; Touitou V; Cassoux N; Marolleau JP; Tamburini J; Houot R; Delwail V; Illerhaus G; Soussain C; Kasenda B
Bone Marrow Transplant; 2017 Aug; 52(8):1113-1119. PubMed ID: 28436974
[TBL] [Abstract][Full Text] [Related]
19. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study.
Majhail NS; Ness KK; Burns LJ; Sun CL; Carter A; Francisco L; Forman SJ; Bhatia S; Baker KS
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1153-9. PubMed ID: 17889351
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
